The ability of ALVAC- or fowlpox-based simian immunodeficiency virus (SIV) vaccines to boost SIV-specific CD4+ and CD8+ T-cell responses was tested in 10 vaccinia-experienced macaques infected with SIVmac251. The CD8+ T-cell response to the dominant Gag181–189 CM9 was quantitated in seven Mamu-A*01-positive macaques by tetramer staining, by ex vivo cytotoxic T-lymphocyte (CTL) activity, and by intracellular cytokine staining (ICS) with the specific Gag181-189 CM9 peptide. The overall CD8+ T-cell response to Gag was assessed using a peptide pool encompassing the entire Gag protein followed by measurement of TNF-α production in ICS assay. Similarly, virus-specific CD4+ T-cell responses were measured by ICS for TNF-α following stimulation with the Gag-overlapping peptide and by proliferative response following stimulation with purified p27 Gag. The two vaccine modalities effectively boosted both CD4+ and CD8+ SIV-specific T-cell response despite prior exposure to the vaccinia-derivative NYVAC vector, suggesting that sequential boosting with either avipox-based vector vaccine candidate is a realistic approach in immune therapy of human immunodeficiency virus type 1 (HIV-1)-infected individuals.
|Titolo:||Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques|
RADAELLI, ANTONIA (Secondo)
|Parole Chiave:||Immunotherapy; Poxvirus; SIVmac251 infection|
|Settore Scientifico Disciplinare:||Settore BIO/19 - Microbiologia Generale|
|Data di pubblicazione:||26-gen-2004|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.vaccine.2003.08.028|
|Appare nelle tipologie:||01 - Articolo su periodico|